UK-based psychedelic research company Beckley Psytech received a USD 50 million strategic investment from clinical-stage biopharmaceutical company atai Life Sciences. The investment is divided into USD 40 million in direct investment and USD 10 million in secondary share purchases, leaving atai with a 35.5% stake in Beckley Psytech.
The funding is aimed at speeding up the development of Beckley Psytech’s clinical-stage, patent-protected psychedelic candidates, BPL-003 and ELE-101, by adding them to atai’s mental health innovation platform. Data from clinical trials for both candidates are expected to be released within 2024.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.